Functional analysis of the ATM-p53-p21 pathway in the LRF CLL4 trial: Blockade at the level of p21 is associated with short response duration

Clinical Cancer Research

Volumn 18, Issue 15, 2012, Pages 4191-4200

  Lin, Ke ^a,b   Adamson, Janet ^b   Johnson, Gillian G ^a,b   Carter, Anthony ^b   Oates, Melanie ^a   Wade, Rachel ^c   Richards, Sue ^c   Gonzalez, David ^d   Matutes, Estella ^d   Dearden, Claire ^d   Oscier, David G ^e   Catovsky, Daniel ^d   Pettitt, Andrew R ^a,b  

^a UNIVERSITY OF LIVERPOOL   (United Kingdom)

^b ROYAL LIVERPOOL AND BROADGREEN UNIVERSITY HOSPITALS NHS TRUST   (United Kingdom)

^c UNIVERSITY OF OXFORD   (United Kingdom)

^d INSTITUTE OF CANCER RESEARCH   (United Kingdom)

^e ROYAL BOURNEMOUTH HOSPITAL   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

ATM PROTEIN; CHLORAMBUCIL; FLUDARABINE; PROTEIN P21; PROTEIN P53;

ADULT; AGED; ARTICLE; ATM GENE; CANCER COMBINATION CHEMOTHERAPY; CANCER PROGNOSIS; CANCER SURVIVAL; CELLULAR DISTRIBUTION; CHRONIC LYMPHATIC LEUKEMIA; CONTROLLED STUDY; DRUG RESPONSE; EX VIVO STUDY; FEMALE; FLOW CYTOMETRY; GENE; GENE DELETION; GENE EXPRESSION; GENE IDENTIFICATION; HUMAN; HUMAN CELL; IGHV GENE; MAJOR CLINICAL STUDY; MALE; MONONUCLEAR CELL; MONOTHERAPY; MUTATIONAL ANALYSIS; OVERALL SURVIVAL; PRIORITY JOURNAL; PROGRESSION FREE SURVIVAL; PROTEIN DETERMINATION; PROTEIN EXPRESSION; PROTEIN FUNCTION; PROTEIN LOCALIZATION; TUMOR SUPPRESSOR GENE; UPREGULATION;

AGED; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; CELL CYCLE PROTEINS; CHLORAMBUCIL; CYCLIN-DEPENDENT KINASE INHIBITOR P21; CYCLOPHOSPHAMIDE; DNA-BINDING PROTEINS; FEMALE; FLOW CYTOMETRY; HUMANS; LEUKEMIA, LYMPHOCYTIC, CHRONIC, B-CELL; LEUKOCYTES, MONONUCLEAR; MALE; MIDDLE AGED; MUTATION; PROGNOSIS; PROTEIN-SERINE-THREONINE KINASES; RANDOMIZED CONTROLLED TRIALS AS TOPIC; SIGNAL TRANSDUCTION; SURVIVAL ANALYSIS; TUMOR SUPPRESSOR PROTEIN P53; TUMOR SUPPRESSOR PROTEINS; VIDARABINE;

EID: 84864476574     PISSN: 10780432     EISSN: 15573265     Source Type: Journal    
DOI: 10.1158/1078-0432.CCR-11-2936     Document Type: Article

References (45)

1. Chiorazzi N, Rai KR, Ferrarini M. Chronic lymphocytic leukemia.NEngl J Med 2005;352:804-15.
2. Zenz T, Mertens D, Küppers R, Döhner H, Stilgenbauer S. From pathogenesis to treatment of chronic lymphocytic leukemia. Nat Rev Cancer 2010;10:37-50.
3. Cramer P, Hallek M. Prognostic factors in chronic lymphocytic leukemia-what do we need to know? Nat Rev Clin Oncol 2011;8:38-47.
4. Vousden KH, Prives C. Blinded by the light: The growing complexity of p53. Cell 2009;137:413-31.
5. Riley T, Sontag E, Chen P, Levine A. Transcriptional control of human p53-regulated genes. Nat Rev Mol Cell Biol 2008;9:402-12. (Pubitemid 351574202)
6. Byrd JC, Gribben JG, Peterson BL, Grever MR, Lozanski G, Lucas DM, et al. Select high-risk genetic features predict earlier progression following chemoimmunotherapy with fludarabine and rituximab in chronic lymphocytic leukemia: justification for risk-adapted therapy. J Clin Oncol 2006;24:437-43. (Pubitemid 46655595)
7. Catovsky D, Richards S, Matutes E, Oscier D, Dyer MJ, Bezares RF, et al. Assessment of fludarabine plus cyclophosphamide for patients with chronic lymphocytic leukaemia (the LRFCLL4 Trial): a randomised controlled trial. Lancet 2007;370:230-9. (Pubitemid 47069536)
8. Grever MR, Lucas DM, Dewald GW, Neuberg DS, Reed JC, Kitada S, et al. Comprehensive assessment of genetic and molecular features predicting outcome in patients with chronic lymphocytic leukemia: results from the US Intergroup Phase III Trial E2997. J Clin Oncol 2007;25:799-804. (Pubitemid 350010635)
9. Hillmen P, Skotnicki AB, Robak T, Jaksic B, Dmoszynska A,WuJ, et al. Alemtuzumab compared with chlorambucil as first-line therapy for chronic lymphocytic leukemia. J Clin Oncol 2007;25:5616-23.
10. Kay NE, Geyer SM, Call TG, Shanafelt TD, Zent CS, Jelinek DF, et al. Combination chemoimmunotherapy with pentostatin, cyclophosphamide, and rituximab shows significant clinical activity with low accompanying toxicity in previously untreated B chronic lymphocytic leukemia. Blood 2007;109:405-11. (Pubitemid 46105933)
11. Bosch F, Ferrer A, Villamor N, González M, Briones J, González-Barca E, et al. Fludarabine, cyclophosphamide, and mitoxantrone as initial therapy of chronic lymphocytic leukemia: high response rate and disease eradication. Clin Cancer Res 2008;14:155-61. (Pubitemid 351377991)
12. Bosch F, Abrisqueta P, Villamor N, Terol MJ, González-Barca E, Ferra C, et al. Rituximab, fludarabine, cyclophosphamide, and mitoxantrone: a new, highly active chemoimmunotherapy regimen for chronic lymphocytic leukemia. J Clin Oncol 2009;27:4578-84.
13. Fischer K, Cramer P, Stilgenbauer S, Busch R, Balleisen L, Kilp J, et al. Bendamustine combined with rituximab (BR) in first-Line therapy of advanced CLL: A multicenter phase II trial of the German CLL Study Group (GCLLSG). Blood 2009;114:(abstr 205).
14. Hallek M, Fischer K, Fingerle-Rowson G, Fink AM, Busch R, Mayer J, et al. Addition of rituximab to fludarabine and cyclophosphamide in patients with chronic lymphocytic leukemia: a randomised, open-label, phase 3 trial. Lancet 2010;376:1164-74.
15. Zenz T, Eichhorst B, Busch R, Denzel T, Häbe S, Winkler D, et al. TP53 mutation and survival in chronic lymphocytic leukemia. J Clin Oncol 2010;28:4473-9.
16. Gonzalez D, Martinez P, Wade R, Hockley S, Oscier D, Matutes E, et al. Mutational status of the TP53 gene as a predictor of response and survival in patients with chronic lymphocytic leukemia: Results from the LRF CLL4 trial. J Clin Oncol 2011;29:2223-9.
17. Zenz T, Kröber A, Scherer K, Häbe S, Bühler A, Benner A, et al. Monoallelic TP53 inactivation is associated with poor prognosis in chronic lymphocytic leukemia: results from a detailed genetic characterization with long-term follow-up. Blood 2008;112:3322-9.
18. Dicker F, Herholz H, Schnittger S, Nakao A, Patten N, Wu L, et al. The detection of TP53 mutations in chronic lymphocytic leukemia independently predicts rapid disease progression and is highly correlated with a complex aberrant karyotype. Leukemia 2009;23:117-24.
19. Malcikova J, Smardova J, Rocnova L, Tichy B, Kuglik P, Vranova V, et al. Monoallelic and biallelic inactivation of TP53 gene in chronic lymphocytic leukemia: selection, impact on survival, and response to DNA damage. Blood 2009;114:5307-14.
20. Rossi D, Cerri M, Deambrogi C, Sozzi E, Cresta S, Rasi S, et al. The prognostic value of TP53 mutations in chronic lymphocytic leukemia is independent of Del17p13: implications for overall survival and chemorefractoriness. Clin Cancer Res 2009;15:995-1004.
21. Zenz T, Häbe S, Denzel T, Mohr J, Winkler D, Bühler A, et al. Detailed analysis of p53 pathway defects in fludarabine-refractory chronic lymphocytic leukemia (CLL): dissecting the contribution of 17p deletion, TP53 mutation, p53-p21 dysfunction, and miR34a in a prospective clinical trial. Blood 2009;114:2589-97.
22. Pettitt AR, Sherrington PD, Stewart G, Cawley JC, Taylor AM, Stankovic T. p53 dysfunction in B-cell chronic lymphocytic leukemia: inactivation of ATM as an alternative to TP53 mutation. Blood 2001;98:814-22.
23. Dotto GP. p21(WAF1/Cip1): more than a break to the cell cycle? Biochim Biophys Acta 2000;1471:M43-56.
24. Carter A, Lin K, Sherrington PD, Pettitt AR. Detection of p53 dysfunction by flow cytometry in chronic lymphocytic leukaemia. Br J Haematol 2004;127:425-8. (Pubitemid 39536594)
25. Carter A, Lin K, Sherrington PD, Atherton M, Pearson K, Douglas A, et al. Imperfect correlation between p53 dysfunction and deletion of TP53 and ATM in chronic lymphocytic leukaemia. Leukemia 2006;20:737-40.
26. Johnson GG, Sherrington PD, Carter A, Lin K, Liloglou T, Field JK, et al. A novel type of p53 pathway dysfunction in chronic lymphocytic leukemia resulting from two interacting single nucleotide polymorphisms within the p21 gene. Cancer Res 2009;69:5210-7.
27. Cheson BD, Bennett JM, Grever M, Kay N, Keating MJ, O'Brien S, et al. National Cancer Institute-sponsored working group guidelines for chronic lymphocytic leukemia: revised guidelines for diagnosis and treatment. Blood 1996;87:4990-7. (Pubitemid 26189840)
28. Best OG, Gardiner AC, Majid A, Walewska R, Austen B, Skowronska A, et al. A novel functional assay using etoposide plus nutlin-3a detects and distinguishes betweenATMand TP53 mutations in CLL. Leukemia 2008;22:1456-9. (Pubitemid 352006096)
29. Le Garff-Tavernier M, Blons H, Nguyen-Khac F, Pannetier M, Brissard M, Gueguen S, et al. Functional assessment of p53 in chronic lymphocytic leukemia. Blood Cancer Journal (2011);1,e5; doi:10.1038/bcj.2011.3Published online 25 February 2011.
30. Oscier D, Wade R, Davis Z, Morilla A, Best G, Richards S, et al. Prognostic factors identified three risk groups in the LRF CLL4 trial, independent of treatment allocation. Haematologica 2010;95:1705-12.
31. Oscier DG, Gardiner AC, Mould SJ, Glide S, Davis ZA, Ibbotson RE, et al. Multivariate analysis of prognostic factors in CLL: clinical stage, IGHV gene mutational status, and loss or mutation of the p53 gene are independent prognostic factors. Blood 2002;100:1177-84. (Pubitemid 34864269)
32. Mohr J, Helfrich H, Fuge M, Eldering E, Bühler A, Winkler D, et al. DNA damage-induced transcriptional program in CLL: biological and diagnostic implications for functional p53 testing. Blood 2011;117:1622-32.
33. Soussi T. p53 alterations in human cancer: more questions than answers. Oncogene 2007;26:2145-56. (Pubitemid 46536642)
34. Skowronska A, Austen B, Powell JE, Weston V, Oscier DJ, Dyer MJS, et al. ATM germline heterozygosity does not play a role in chronic lymphocytic leukemia initiation but influences rapid disease progression through loss of the remaining ATM allele. Haematologica 2012;97:142-6.
35. Romanov VV, James CH, Sherrington PD, Pettitt AR. Basic fibroblast growth factor suppresses p53 activation in the neoplastic cells of a proportion of patients with chronic lymphocytic leukaemia. Oncogene 2005;24:2855-60.
36. Zhuang J, Hawkins SF, Glenn MA, Lin K, Johnson GG, Carter A, et al. Akt is activated in chronic lymphocytic leukemia cells and delivers a pro-survival signal: the therapeutic potential of Akt inhibition. Haematologica 2010;95:110-8.
37. Zent CS. Time to test CLL p53 function. Blood 2010;115:4154-5.
38. Valganon M, Giraldo P, Agirre X, Larrayoz MJ, Rubio-Martinez A, Rubio-Felix D, et al. p53 aberrations do not predict individual response to fludarabine in patients with B-cell chronic lymphocytic leukaemia in advanced stages Rai III/IV. Br J Haematol 2005;129:53-9. (Pubitemid 40524051)
39. Clarke AR, Purdie CA, Harrison DJ, Morris RG, Bird CC, Hooper ML, et al. Thymocyte apoptosis induced by p53-dependent and independent pathways. Nature 1993;362:849-52. (Pubitemid 23132162)
40. Lowe SW, Ruley HE, Jacks T, Housman DE. p53-dependent apoptosis modulates the cytotoxicity of anticancer agents. Cell 1993;74:957-67. (Pubitemid 23289454)
41. Pettitt AR, Clarke AR, Cawley JC, Griffiths SD. Purine analogues kill resting lymphocytes by p53-dependent and -independent mechanisms. Br J Haematol 1999;105:986-8. (Pubitemid 29309106)
42. Meek DW. Tumour suppression by p53: a role for the DNA damage response? Nat Rev Cancer 2009;9:714-23.
43. Gu Y, Turck CW, Morgan DO. Inhibition of CDK2 activity in vivo by an associated 20K regulatory subunit. Nature 1993;366:707-10. (Pubitemid 24036022)
44. Harper JW, Elledge SJ, Keyomarsi K, Dynlacht B, Tsai LH, Zhang P, et al. Inhibition of cyclin-dependent kinases by p21. Mol Biol Cell 1995;6:387-400.
45. Döhner H, Stilgenbauer S, Benner A, Leupolt E, Kröber A, Bullinger L, et al. Genomic aberrations and survival in chronic lymphocytic leukemia. N Engl J Med 2000;343:1910-6. (Pubitemid 32064784)